Merck secures EC approval for Keytruda in combination therapy for lung cancer
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination ... Read More
AstraZeneca’s Imfinzi garners positive opinion from CHMP for NSCLC treatment
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a ... Read More
AstraZeneca’s Tagrisso secures FDA breakthrough therapy designation for first-line treatment of NSCLC
AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the ... Read More
FDA approves Merck’s Keytruda in combination with chemotherapy for advanced lung cancer treatment
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination with chemotherapy, as a first-line treatment option ... Read More
FDA accelerates review of Novartis’s Zykadia for first-line treatment in lung cancer
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority ... Read More
Genprex announces promising results for Oncoprex in Phase II lung cancer trial
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted ... Read More
Smokers with Diabetes have high risk of early death!
As per the recent study by Kavita Garg, an Indian-origin researcher at the University of Colorado-Denver in US, diabetic persons with heavy smoking habit have ... Read More